<DOC>
	<DOCNO>NCT00041808</DOCNO>
	<brief_summary>MTC-DOX Doxorubicin DOX , chemotherapy drug , adsorb , make “ stick ” , magnetic bead ( MTCs ) . MTCs tiny , microscopic particle iron carbon . When DOX add MTCs , DOX attach carbon part MTCs . MTC-DOX direct deposited area tumor , think `` leak '' blood vessel wall . Once surround tissue , think Doxorubicin become `` free '' magnetic bead able act tumor cell . The iron component particle magnetic property , make possible direct MTC-DOX specific tumor sit liver placing magnet body surface . It hop MTC-DOX use magnet may target chemotherapy drug directly liver tumor provide treatment patient cancer spread liver .</brief_summary>
	<brief_title>Magnetic-Targeted Doxorubicin Treating Patients With Cancer Metastatic Liver</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Inclusion Criteria Patients Karnofsky ( equivalent ) performance status &gt; 60 expect survival &gt; 2 month Patients agree use medically effective method contraception Patients able understand give write informed consent The center tumor mass must &lt; = 14 cm anterior lateral abdominal wall determine cross sectional imaging measure baseline . This required optimal retention MTCDOX magnetic field . If one tumor mass present , treat tumor mass must meet criterion Exclusion Criteria Women pregnant lactate Patient ’ metastatic liver cancer , primary liver cancer exclude HCC , diffuse disease focal area ( ) conducive local regional therapy Patients follow laboratory abnormality : Hemoglobin &lt; 10.0 g/dL ; Granulocyte count &lt; 1,500 per mm3 ; Platelet count &lt; 50,000 per mm3 ; Lymphocyte count &lt; 0.5 x 10 9th per L ; Total bilirubin &gt; /= 3.0 mg/dL ; AST ALT &gt; /= 5x upper limit normal ; INR &gt; /= 1.3 ; Creatinine &gt; /= 2.0 mg/dL Patients either significant cardiovascular disease organ system dysfunction , opinion investigator , would either compromise patient 's safety interfere evaluation test material . Patients evidence myocardial infarction within six ( 6 ) month prior trial exclude . Patients indwell cardiac pacemaker , cerebral aneurysm clip , indwell device appliance could adversely affect use external magnet Patients time study entry second invasive cancer basal cell squamous cell carcinoma skin , carcinoma situ cervix Patients document evidence hemachromatosis hemosiderosis Patients CT ultrasound evidence portal vein invasion thrombosis Patients prior anthracycline therapy leave ventricular ejection fraction ( LVEF ) &lt; 50 % , measure either multigated radionuclide angiography ( MUGA ) scan echocardiogram .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2003</verification_date>
	<keyword>Metastatic liver cancer</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>esophageal cancer</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>malignant melanoma</keyword>
	<keyword>sarcoma</keyword>
	<keyword>GIST</keyword>
	<keyword>gastrointestinal stromal tumor</keyword>
	<keyword>lung cancer</keyword>
	<keyword>liver cancer</keyword>
</DOC>